David J. Hermel

Learn More
This study explores our Familial Cancer Program’s experience implementing multi-gene panel testing in a largely rural patient population. We conducted a retrospective review of patients undergoing panel testing between May 2011 and August 2015. Our goal was to evaluate factors that might be predictors of identifying variants (pathogenic or uncertain(More)
Both immune checkpoint inhibitors and molecularly targeted agents have dramatically improved clinical outcomes for patients with metastatic melanoma. These two therapeutic approaches harness distinct mechanistic pathways—on the one hand, monoclonal antibodies against the immune checkpoints CTLA-4 and PD-1/PD-L1 stimulate the T cell mediated host immune(More)
There is one other scenario in which a negative panel test can change management. Some cancer risk models (e.g., the Tyrer-Cuzick model, [5]) incorporate genetic results as one parameter to determine risk. A negative panel test could lower risk for some individuals from just above to just below the 20% threshold that could affect screening recommendations.(More)
INTRODUCTION We performed the present study to better understand the practices and preferences of women with an elevated risk of breast cancer by merging the registries from 2 separate institutions and comparing the clinical characteristics and outcomes. MATERIALS AND METHODS The data from women enrolled in institutional review board-approved registries(More)
  • 1